SAN DIEGO, July 29, 2014 -- Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application for the clinical development of PROHEMAA in pediatric ... (more)
http://ift.tt/1qmK5Hd
http://ift.tt/1qmK5Hd
No comments:
Post a Comment